Table 1.
Oncogene-specific phosphoactivation of tyrosine kinases and phosphatases
| Oncogene combination | Tyrosine kinase (phosphoresidue) | Tyrosine phosphatase (phosphoresidue) | Functional significance* |
| AKT/ERG | EGFR (Y1172) | PTPN11 (Y584) | Enzymatic activation |
| PTPRA (Y825) | Enzymatic activation | ||
| INPPL1 (Y1136) | Unknown | ||
| AKT/AR | JAK2 (Y1007/08)† | PTPN11 (Y62) | Enzymatic activation |
| AKT/KRASG12V | EPHA2 (Y595) | Enzymatic activation | |
| LYN (Y508) | Enzymatic inhibition | ||
| PTK2B (Y579) | Unknown | ||
| PTK2B (Y849) | Unknown | ||
| EPHA2 (Y773) | Unknown | ||
| AKT/ERG | FER (Y402) | Alters cell motility | |
| AKT/AR | |||
| AKT/KRASG12V | |||
All measured phosphorylation events are relative to AKT-only lesions.
*Source: Phosphosite (http://www.phosphosite.org).
†JAK2 was not identified by MS, but inferred on the basis of high STAT3 Y705 phosphorylation observed in AKT/AR tumors.